The effect of probiotic and/or prebiotic on liver function tests in patients with nonalcoholic fatty liver disease: A double blind randomized clinical trial

Iranian Red Crescent Medical Journal

Volumn 19, Issue 4, 2017, Pages

  Javadi, Leila ^a   Ghavami, Mostafa ^b   Khoshbaten, Manouchehr ^c   Safaiyan, Abdolrasoul ^d   Barzegari, Abolfazl ^e   Gargari, Bahram Pourghassem ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d NONE   (Iran)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Liver function; NAFLD; Prebiotic; Probiotic; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; INULIN; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT;

ADULT; ARTICLE; BIFIDOBACTERIUM LONGUM; BIOCHEMICAL ANALYSIS; BODY MASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ECHOGRAPHY; FEMALE; HUMAN; LACTOBACILLUS ACIDOPHILUS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; TREATMENT OUTCOME; WAIST HIP RATIO;

EID: 85018394793     PISSN: 20741804     EISSN: 20741812     Source Type: Journal    
DOI: 10.5812/ircmj.46017     Document Type: Article

References (41)

1. Mouzaki M, Allard JP. The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease. J Clin Gastroenterol. 2012;46(6):457-67. doi: 10.1097/MCG.0b013e31824cf51e. [PubMed: 22469640].
2. Malhotra N, Beaton MD. Management of non-alcoholic fatty liver disease in 2015. World J Hepatol. 2015;7(30):2962-7. doi: 10.4254/wjh.v7.i30.2962. [PubMed: 26730275].
3. Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7(12):691-701. doi: 10.1038/nrgastro.2010.172. [PubMed: 21045794].
4. Moschen AR, Kaser S, Tilg H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab. 2013;24(11):537-45. doi: 10.1016/j.tem.2013.05.009. [PubMed: 23827477].
5. Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JI, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr. 2011;94(1):58-65. doi: 10.3945/ajcn.110.010132. [PubMed: 21543530].
6. Hoverstad T, Midtvedt T. Short-chain fatty acids in germfree mice and rats. J Nutr. 1986;116(9):1772-6. [PubMed: 3761032].
7. Daly K, Proudman CJ, Duncan SH, Flint HJ, Dyer J, Shirazi-Beechey SP. Alterations in microbiota and fermentation products in equine large intestine in response to dietary variation and intestinal disease. Br J Nutr. 2012;107(7):989-95. doi: 10.1017/S0007114511003825. [PubMed: 21816118].
8. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-72. doi: 10.2337/db06-1491. [PubMed: 17456850].
9. Group JFWW. Guidelines for the evaluation of probiotics in food: report of a jointFAO/WHOworking groupondrafting guidelines for the evaluation of probiotics in food, London, Ontario, Canada.; 2014.
10. Parnell JA, Raman M, Rioux KP, Reimer RA. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int. 2012;32(5):701-11. doi: 10.1111/j.1478-3231.2011.02730.x. [PubMed: 22221818].
11. Scott KP, Gratz SW, Sheridan PO, Flint HJ, Duncan SH. The influence of diet on the gut microbiota. Pharmacol Res. 2013;69(1):52-60. doi: 10.1016/j.phrs.2012.10.020. [PubMed: 23147033].
12. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012;57(2):545-53. doi: 10.1007/s10620-011-1887-4. [PubMed: 21901256].
13. Pompei A, Cordisco L, Raimondi S, Amaretti A, Pagnoni UM, Matteuzzi D, et al. In vitro comparison of the prebiotic effects of two inulin-type fructans. Anaerobe. 2008;14(5):280-6. doi: 10.1016/j.anaerobe.2008.07.002. [PubMed: 18713652].
14. Houghton D, Stewart CJ, Day CP, Trenell M. Gut Microbiota and Lifestyle Interventions in NAFLD. Int J Mol Sci. 2016;17(4):447. doi: 10.3390/ijms17040447. [PubMed: 27023533].
15. Kolida S, Gibson GR. Prebiotic capacity of inulin-type fructans. J Nutr. 2007;137(11 Suppl):2503S-6S. [PubMed: 17951493].
16. Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for nonalcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev. 2007(1):CD005165. doi: 10.1002/14651858.CD005165.pub2. [PubMed: 17253543].
17. Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7(3):559-65. doi: 10.4254/wjh.v7.i3.559. [PubMed: 25848479].
18. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ. 2004;328(7446):983. doi: 10.1136/bmj.38050.593634.63. [PubMed: 15028636].
19. Liu JE, Zhang Y, Zhang J, Dong PL, Chen M, Duan ZP. Probiotic yogurt effects on intestinal flora of patients with chronic liver disease. Nurs Res. 2010;59(6):426-32. doi: 10.1097/NNR.0b013e3181fa4dc6. [PubMed: 21048484].
20. Li F, Wilkens LR, Novotny R, Fialkowski MK, Paulino YC, Nelson R, et al. Anthropometric measurement standardization in the US-affiliated pacific: Report from the Children’s Healthy Living Program. AmJHum Biol. 2016;28(3):364-71. doi: 10.1002/ajhb.22796. [PubMed: 26457888].
21. Khov N, Sharma A, Riley TR. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(22):6821-5. doi: 10.3748/wjg.v20.i22.6821. [PubMed: 24944472].
22. Tarantino G, Finelli C. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbiol. 2015;10(5):889-902. doi: 10.2217/fmb.15.13. [PubMed: 26000656].
23. Lambert JE, Parnell JA, Eksteen B, Raman M, Bomhof MR, Rioux KP, et al. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. BMC Gastroenterol. 2015;15:169. doi: 10.1186/s12876-015-0400-5. [PubMed: 26635079].
24. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011;15(9):1090-5. [PubMed: 22013734].
25. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013;19(40):6911-8. doi: 10.3748/wjg.v19.i40.6911. [PubMed: 24187469].
26. Nabavi S, Rafraf M, Somi MH, Homayouni-Rad A, Asghari-Jafarabadi M. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J Dairy Sci. 2014;97(12):7386-93. doi: 10.3168/jds.2014-8500. [PubMed: 25306266].
27. Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesityrelated liver disease. J Pediatr Gastroenterol Nutr. 2011;52(6):740-3. doi: 10.1097/MPG.0b013e31821f9b85. [PubMed: 21505361].
28. Gao X, Zhu Y, Wen Y, Liu G, Wan C. Efficacy of probiotics in nonalcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials. Hepatol Res. 2016;46(12):1226-33. doi: 10.1111/hepr.12671. [PubMed: 26866817].
29. Machado MV, Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol. 2012;11(4):440-9. [PubMed: 22700625].
30. Buss C, Valle-Tovo C, Miozzo S, Alves de Mattos A. Probiotics and synbiotics may improve liver aminotransferases levels in non-alcoholic fatty liver disease patients. Ann Hepatol. 2014;13(5):482-8. [PubMed: 25152979].
31. Duseja A, Chawla YK. Obesity and NAFLD: the role of bacteria and microbiota. Clin Liver Dis. 2014;18(1):59-71. doi: 10.1016/j.cld.2013.09.002. [PubMed: 24274865].
32. Vos MB. Nutrition, nonalcoholic fatty liver disease and the microbiome: recent progress in the field. Curr Opin Lipidol. 2014;25(1):61-6. doi: 10.1097/MOL.0000000000000043. [PubMed: 24366230].
33. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58(8):1091-103. doi: 10.1136/gut.2008.165886. [PubMed: 19240062].
34. Farhadi A, Gundlapalli S, Shaikh M, Frantzides C, Harrell L, Kwasny MM, et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int. 2008;28(7):1026-33. doi: 10.1111/j.1478-3231.2008.01723.x. [PubMed: 18397235].
35. Alisi A, Manco M, Devito R, Piemonte F, Nobili V. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2010;50(6):645-9. doi: 10.1097/MPG.0b013e3181c7bdf1. [PubMed: 20400911].
36. Sabate JM, Jouet P, Harnois F, Mechler C, Msika S, Grossin M, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg. 2008;18(4):371-7. doi: 10.1007/s11695-007-9398-2. [PubMed: 18286348].
37. Henao-Mejia J, Elinav E, Thaiss CA, Licona-Limon P, Flavell RA. Role of the intestinal microbiome in liver disease. J Autoimmun. 2013;46:66-73. doi: 10.1016/j.jaut.2013.07.001. [PubMed: 24075647].
38. Garner CE, Smith S, de Lacy Costello B, White P, Spencer R, Probert CS, et al. Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. FASEB J. 2007;21(8):1675-88. doi: 10.1096/fj.06-6927com. [PubMed: 17314143].
39. Roberfroid MB. Inulin-type fructans: functional food ingredients. J Nutr. 2007;137(11 Suppl):2493S-502S. [PubMed: 17951492].
40. Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM, et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut. 2013;62(8):1112-21. doi: 10.1136/gutjnl-2012-303304. [PubMed: 23135760].
41. Shavakhi A, Minakari M, Firouzian H, Assali R, Hekmatdoost A, Ferns G. Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial. Int J Prev Med. 2013;4(5):531-7. [PubMed: 23930163].